| Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? G Lawlor, AC Moss Inflammatory bowel diseases 16 (9), 1620-1627, 2010 | 298 | 2010 |
| Histologic markers of inflammation in patients with ulcerative colitis in clinical remission L Rosenberg, KS Nanda, T Zenlea, A Gifford, GO Lawlor, KR Falchuk, ... Clinical Gastroenterology and Hepatology 11 (8), 991-996, 2013 | 136 | 2013 |
| Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission L Rosenberg, GO Lawlor, T Zenlea, JD Goldsmith, A Gifford, KR Falchuk, ... Inflammatory bowel diseases 19 (4), 779-784, 2013 | 98 | 2013 |
| Enteric infections are common in patients with flares of inflammatory bowel disease JE Axelrad, A Joelson, PHR Green, G Lawlor, S Lichtiger, K Cadwell, ... Official journal of the American College of Gastroenterology| ACG 113 (10 …, 2018 | 87 | 2018 |
| ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion AC Moss, G Lawlor, D Murray, D Tighe, SF Madden, AM Mulligan, ... Biochemical and biophysical research communications 345 (1), 216-221, 2006 | 65 | 2006 |
| Thiopurines and inflammatory bowel disease: current evidence and a historical perspective JE Axelrad, A Roy, G Lawlor, B Korelitz, S Lichtiger World journal of gastroenterology 22 (46), 10103, 2016 | 64 | 2016 |
| CD 73 is a phenotypic marker of effector memory T h17 cells in inflammatory bowel disease GA Doherty, A Bai, D Hanidziar, MS Longhi, GO Lawlor, P Putheti, ... European journal of immunology 42 (11), 3062-3072, 2012 | 63 | 2012 |
| Acute venous thromboembolism risk highest within 60 days after discharge from the hospital in patients with inflammatory bowel diseases AS Faye, T Wen, AN Ananthakrishnan, S Lichtiger, GG Kaplan, ... Clinical Gastroenterology and Hepatology 18 (5), 1133-1141. e3, 2020 | 58 | 2020 |
| Enteric infection in relapse of inflammatory bowel disease: the utility of stool microbial PCR testing JE Axelrad, A Joelson, YR Nobel, G Lawlor, PHR Green, S Lichtiger, ... Inflammatory Bowel Diseases 23 (6), 1034-1039, 2017 | 48 | 2017 |
| Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD AS Faye, T Wen, A Soroush, AN Ananthakrishnan, R Ungaro, G Lawlor, ... Digestive diseases and sciences, 1-13, 2021 | 44 | 2021 |
| Use of methotrexate in inflammatory bowel disease in 2014: A User’s Guide A Swaminath, R Taunk, G Lawlor World Journal of Gastrointestinal Pharmacology and Therapeutics 5 (3), 113, 2014 | 41 | 2014 |
| Incident rates of colonic neoplasia in older patients: when should we stop screening? GC Harewood, GO Lawlor, MV Larson Journal of gastroenterology and hepatology 21 (6), 1021-1025, 2006 | 36 | 2006 |
| Minor hematochezia decreases use of venous thromboembolism prophylaxis in patients with inflammatory bowel disease AS Faye, KW Hung, K Cheng, JW Blackett, AS Mckenney, AR Pont, J Li, ... Inflammatory bowel diseases 26 (9), 1394-1400, 2020 | 35 | 2020 |
| MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2 G Lawlor, PP Doran, P MacMathuna, DW Murray Journal of Experimental & Clinical Cancer Research 29, 1-5, 2010 | 30 | 2010 |
| The real-world effectiveness and safety of ustekinumab in the treatment of Crohn's disease: results from the SUCCESS consortium AM Johnson, M Barsky, W Ahmed, S Zullow, J Galati, V Jairath, N Narula, ... Official journal of the American College of Gastroenterology| ACG 118 (2 …, 2023 | 27 | 2023 |
| Bariatric surgery is associated with increased risk of new‐onset inflammatory bowel disease: case series and national database study R Ungaro, R Fausel, HL Chang, S Chang, LA Chen, A Nakad, A El Nawar, ... Alimentary pharmacology & therapeutics 47 (8), 1126-1134, 2018 | 27 | 2018 |
| Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio‐economic factors M Agrawal, S Cohen‐Mekelburg, M Kayal, J Axelrad, J Galati, B Tricomi, ... Alimentary pharmacology & therapeutics 49 (5), 564-571, 2019 | 23 | 2019 |
| Hormone therapy for cancer is a risk factor for relapse of inflammatory bowel diseases JE Axelrad, A Bazarbashi, J Zhou, D Castañeda, A Gujral, D Sperling, ... Clinical Gastroenterology and Hepatology 18 (4), 872-880. e1, 2020 | 20 | 2020 |
| Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile DJ Lukin, G Lawlor, DP Hudesman, L Durbin, JE Axelrad, M Passi, ... Inflammatory bowel diseases 25 (4), 775-781, 2019 | 20 | 2019 |
| The distribution of enteric infections utilizing stool microbial polymerase chain reaction testing in clinical practice JE Axelrad, A Joelson, Y Nobel, S Whittier, G Lawlor, MS Riddle, ... Digestive Diseases and Sciences 63, 1900-1909, 2018 | 17 | 2018 |
